Royalty Pharma plc Class A Ordinary Shares (RPRX) fair value

ACCE thesis

Royalty Pharma buys the right to future sales royalties on approved and late-stage drugs, so it collects a share of revenue from products like Biogen's and Vertex's without carrying R&D or manufacturing costs, which explains the 95.8% gross margin. The moat is the portfolio itself: a large, diversified set of royalty and milestone interests that gives it first look at new deals and a long tail of cash flows that is hard for a smaller royalty buyer to replicate. Revenue growth of 16.5% is the number to pressure-test, since it depends on how much of that comes from new acquisitions versus organic growth in existing royalties, and the 30.7 trailing P/E against a 10.0 forward P/E suggests earnings are expected to step up sharply. At a $33.4B market cap with a 14.0% ROE and a 19.8% operating margin, the stock looks inexpensive on forward earnings, but the gap between trailing and forward multiples is large enough that the forecast assumptions deserve a close read before anyone leans on them. It is not in any major index, which may keep it under-owned, and that combination of a cash-generative royalty model and a forward valuation that screens cheap merits a deeper look at the deal pipeline and the durability of its top royalty streams.